BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prasuhn J, Brüggemann N. Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson's Disease. Genes (Basel) 2021;12:1840. [PMID: 34828446 DOI: 10.3390/genes12111840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 D’souza A, Nozohouri S, Bleier BS, Amiji MM. CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood–Brain Barrier and Towards Specific Cellular Targeting. Pharm Res 2022. [DOI: 10.1007/s11095-022-03433-5] [Reference Citation Analysis]
2 Pizarro-Galleguillos BM, Kunert L, Brüggemann N, Prasuhn J. Iron- and Neuromelanin-Weighted Neuroimaging to Study Mitochondrial Dysfunction in Patients with Parkinson's Disease. Int J Mol Sci 2022;23. [PMID: 36430157 DOI: 10.3390/ijms232213678] [Reference Citation Analysis]
3 Zhang C, Chen S, Li X, Xu Q, Lin Y, Lin F, Yuan M, Zi Y, Cai J. Progress in Parkinson's disease animal models of genetic defects: Characteristics and application. Biomedicine & Pharmacotherapy 2022;155:113768. [DOI: 10.1016/j.biopha.2022.113768] [Reference Citation Analysis]
4 Prasuhn J, Kunert L, Brüggemann N. Neuroimaging Methods to Map In Vivo Changes of OXPHOS and Oxidative Stress in Neurodegenerative Disorders. IJMS 2022;23:7263. [DOI: 10.3390/ijms23137263] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Yang X, Yang R, Zhang F. Role of Nrf2 in Parkinson’s Disease: Toward New Perspectives. Front Pharmacol 2022;13:919233. [DOI: 10.3389/fphar.2022.919233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Takahashi S, Mashima K. Neuroprotection and Disease Modification by Astrocytes and Microglia in Parkinson Disease. Antioxidants 2022;11:170. [DOI: 10.3390/antiox11010170] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]